Who Paid My Doc Search
Menu
Organisation paid for research Program year 2022 Source: CMS Open Payments

American Research LLC

Neither a doctor nor a teaching hospital

Research payments

$38,546

33 payments

Through program year 2022, American Research LLC is reported as receiving $38,546 in research payments, across 33 payments.

By program year

4 rows
Year Kind Amount Payments
2022 Research $176 1
2021 Research $6,294 12
2020 Research $3,695 3
2019 Research $28,381 17

Breakdown

Who paid Research payments · program years 2019–2022
  1. Akebia Therapeutics Inc $21,792 12 payments
  2. Eli Lilly and Company $11,974 17 payments
  3. Allergan Inc. $4,780 4 payments
Studies the money was for Research payments · program years 2019–2022
  1. Akb-6548-Ci-0015 $11,437 7 payments
  2. Akb-6548-Ci-0014 $8,154 4 payments
  3. A Phase 2, Randomized, Parallel, Open-Label Comparator Controlled Trial to Evaluate the Safety and Efficacy of Ly3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy $4,668 1 payment
  4. A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis $3,601 2 payments
  5. A Study of Tirzepatide (Ly3298176) Once A Week Versus Insulin Glargine Once A Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk $3,072 3 payments
  6. Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Correction) $2,200 1 payment
  7. A Randomized, Double-Blind Study With An Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Pediatric Patients With Type 2 Diabetes Mellitus (Award-Peds: Assessment of Weekly Administration of Ly2189265 in Diabetes-Pediatric Study) $1,876 3 payments
  8. A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease Ad Geras US $1,816 1 payment
  9. A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $990 1 payment
  10. A Randomized, Double-Blind Study With An Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Pediatric Patients With Type 2 Diabetes Mellitus-Award-Peds- Assessment of Weekly Administration of Ly2189265 in Diabetes-Pediatric Study $281 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record